Table 2 Mean +/− SD age at onset, death and duration of illness, and gender composition, for each neuropathological and genetic subgroup of patients. Mean +/− SD and median (in parentheses) post mortem delay interval (PMI) is also presented for each group
Group | M/F | Onset (y) | Death (y) | Duration (y) | PMI (h) |
|---|---|---|---|---|---|
FTLD-TDP type A (n = 30) | 17/13 | 60.7 ± 6.2 | 68.7 ± 6.1 | 8.0 ± 3.0 | 59.5 ± 33.3 (57) |
FTLD-TDP type B (n = 18) | 9/9 | 59.7 ± 8.0 | 65.2 ± 9.2 | 5.6 ± 5.5 | 70.6 ± 40.6 (50) |
FTLD-TDP type C (n = 21) | 12/9 | 59.7 ± 7.9 | 71.8 ± 5.3 | 12.1 ± 5.1 | 54.7 ± 35.1 (44) |
FTLD-tau (n = 11) | 4/7 | 51.4 ± 6.4 | 61.4 ± 5.4 | 10.0 ± 3.1 | 45.8 ± 24.0 (44) |
FTLD C9orf72 expansion (n = 16) | 8/8 | 58.8 ± 5.3 | 65.7 ± 4.4 | 6.9 ± 4.6 | 66.1 ± 21.9 (72) |
FTLD GRN mutation (n = 10) | 6/4 | 59.5 ± 6.4 | 67.9 ± 5.9 | 8.4 ± 3.7 | 42.1 ± 29.2 (32) |
FTLD No mutation (n = 42) | 23/19 | 60.7 ± 7.9 | 70.0 ± 8.1 | 9.3 ± 5.5 | 62.6 ± 40.2 (48) |
FTLD MAPT mutation (n = 11) | 4/7 | 51.4 ± 6.4 | 61.4 ± 5.4 | 10.0 ± 3.1 | 45.8 ± 24.0 (44) |
FTLD TBK1 mutation (n = 1) | 1/0 | 62 | 72 | 10 | 97 |
Healthy Controls (n = 10) | 3/7 | na | 83.3 ± 7.6 | na | 64.4 ± 35.0 (50.5) |